Dr. Brandao meets Prof. Heather Wakelee: KEYNOTE 671
In a remarkable discussion Dr Brandao from the Institut Jules Bordet, Brussels challenges Prof Dr Heather Wakelee from the Stanford Cancer Institute on the results of the KEYNOTE-671 study.
In patients with NSCLC, pembrolizumab has shown efficacy as mono-therapy in the adjuvant and advanced settings and in combination with chemotherapy in metastatic disease. KEYNOTE-671 evaluated the addition of pembrolizumab to platinum-based chemo as neoadjuvant therapy followed by resection and pembrolizumab vs placebo as adjuvant therapy in patients with early-stage NSCLC.
With the educational support of:
